- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | MSD competes with Pfizer in pneumococcal vaccine market after FDA approval | ||
| Di | Ability Biologics closes extended $18m seed funding round | ||
| Di | Pharmaceutical cleaning equipment, agents and services | ||
| Di | Sanofi and Belharra forge $700m partnership for immunological diseases | ||
| Di | Pyros wins FDA approval for ready-to-use infantile spasm treatment | ||
| Di | The lasting impacts of the pandemic on cybersecurity in healthcare | ||
| Di | Johnson & Johnson submits BLA to FDA for lung cancer drug | ||
| Di | Q&A with Springer Nature's Leslie Lansman: Ethical content sharing and the benefits of the CLA Pharmaceutical Licence | ||
| Di | RevOpsis and Kemwell partner to boost biologic development | ||
| Di | Charles River and Captain T Cell sign vector production agreement | ||
| Di | FDA approves MSD's KEYTRUDA for advanced endometrial cancer | ||
| Di | Can supermarket pharmacies plug urgent healthcare gaps? | ||
| Di | Olanzapine by Neurelis for Bipolar Disorder (Manic Depression): Likelihood of Approval | ||
| Di | Omalizumab biosimilar by Teva Pharmaceutical Industries for Chronic Urticaria Or Hives: Likelihood of Approval | ||
| Di | Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of Approval | ||
| Di | MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval | ||
| Di | OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of Approval | ||
| Di | OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): Likelihood of Approval | ||
| Di | MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval | ||
| Mo | Zifanocycline by KBP Biosciences for Acinetobacter Infections: Likelihood of Approval | ||
| Mo | Lifirafenib maleate by BeiGene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval | ||
| Mo | VXA-901 by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval | ||
| Mo | Tenalisib by Rhizen Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval | ||
| Mo | Tenalisib by Rhizen Pharmaceuticals for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval | ||
| Mo | Tenalisib by Rhizen Pharmaceuticals for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
